Transformer-based AI technology improves early ovarian cancer diagnosis using cfDNA methylation markers.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 39094578.
- Also identified by DOI 10.1016/j.xcrm.2024.101666 and PMC identifier 11384945.
- Licence recorded as CC BY-NC-ND.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Epithelial ovarian cancer (EOC) is the deadliest women's cancer and has a poor prognosis. Early detection is the key for improving survival (a 5-year survival rate in stage I/II is over 70% compared to that of 25% in stage III/IV) and can be achieved through methylation markers from circulating cell-free DNA (cfDNA) using a liquid biopsy. In this study, we first identify top 500 EOC markers differentiating EOC from healthy female controls from 3.3 million methylome-wide CpG sites and validated them in 1,800 independent cfDNA samples. We then utilize a pretrained AI transformer system called MethylBERT to develop an EOC diagnostic model which achieves 80% sensitivity and 95% specificity in early-stage EOC diagnosis. We next develop a simple digital droplet PCR (ddPCR) assay which archives good performance, facilitating early EOC detection.
Medical subject headings
- DNA Methylation
- Biomarkers, Tumor
- Ovarian Neoplasms
- Early Detection of Cancer
- Cell-Free Nucleic Acids